Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Proposes a Merger With Gilead Sciences

By Cory Renauer – Jun 7, 2020 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A tie-up between the two would be the largest healthcare deal in history.

The coronavirus pandemic put a stranglehold on big pharma dealmaking, but it looks like the logjam's about to break. AstraZeneca (AZN 0.41%) has spoken with Gilead Sciences (GILD 0.47%) about forming a gigantic biopharmaceutical powerhouse.

The biggest deal yet

People familiar with the matter told Bloomberg that the big British drugmaker informally floated the idea with Gilead in May to gauge interest. No terms have been discussed, but this would be the largest deal the healthcare sector has ever seen.

Hand held to an ear.

Image source: Getty Images.

Gilead's market cap ranged between $91 billion and $101 billion last month and most biopharmaceutical buyout offers come with 40% to 60% premiums. Before assuming the deal will happen, though, it's important to realize Gilead's not interested in selling, and the California headquartered company certainly doesn't need help making money in this industry.

Hungry for profits now

Lynparza's recent approval to treat prostate cancer and Tagrisso's likely approval as a post-surgical adjuvant for early stage lung cancer patients will push Astra's bottom line much higher in the years ahead. At the moment, though, the British pharma isn't nearly as profitable as Gilead.

Although sales of Gilead's lead hepatitis C antiviral drugs have been squeezed by competition, its HIV franchise, led by Biktarvey, helped Gilead deliver $8.2 billion in free cash flow over the past year. That was 481% more profits to pay dividends and acquire rivals than Astra's operations produced over the same time frame. 

The merger could also make AstraZeneca a COVID-19 powerhouse. The FDA recently authorized Gilead's remdesivir for emergency treatment of COVID-19 and Astra's prepared to produce 2 billion doses of a SARS-CoV-2 vaccine that could protect people from infection in the first place.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.63 (0.47%) $0.29
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$53.24 (0.41%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.